<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22473" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>H2 Blockers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nugent</surname>
            <given-names>Caitlin C.</given-names>
          </name>
          <aff>University of Louisiana at Monroe</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Falkson</surname>
            <given-names>Samuel R.</given-names>
          </name>
          <aff>Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Terrell</surname>
            <given-names>Jamie M.</given-names>
          </name>
          <aff>University of LA Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caitlin Nugent declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Falkson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jamie Terrell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22473.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">H2 receptor blockers, or histamine-2 receptor antagonists (H2RAs), are gastric acid-suppressing agents frequently used to treat various gastric conditions. The U.S. Food and Drug Administration has approved the short-term administration&#x000a0;of H2RAs for patients with uncomplicated gastroesophageal reflux disease (GERD), gastric or duodenal ulcers, gastric hypersecretion, and mild to infrequent heartburn or indigestion. H2RAs may also be used off-label for stress ulcer prophylaxis, esophagitis, gastritis, gastrointestinal bleeding, or urticaria. H2RAs are sometimes part of a multidrug regimen for <italic toggle="yes">Helicobacter pylori</italic> eradication.</p>
        <p>In the United States, 3 H2RAs are&#x000a0;FDA-approved and available either over-the-counter (OTC) or by prescription: famotidine, cimetidine, and nizatidine. Depending on the dose, famotidine and cimetidine&#x000a0;may require a prescription. Higher doses of nizatidine require a prescription.&#x000a0;A&#x000a0;solid clinical understanding of&#x000a0;H2RAs is crucial for effectively managing gastrointestinal disorders.&#x000a0;This activity describes the&#x000a0;pharmacological features&#x000a0;of H2 blockers and emphasizes the interprofessional team's role in promoting their safety, equipping healthcare professionals with essential knowledge, and enhancing patient outcomes and care standards.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate&#x000a0;the mechanism of action of H2 receptor blockers.</p></list-item><list-item><p>Assess&#x000a0;the adverse&#x000a0;drug reactions&#x000a0;associated with H2 receptor blocker administration.</p></list-item><list-item><p>Identify&#x000a0;the indications for H2 receptor blocker therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from H2 receptor blockers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22473">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22473.s2" sec-type="Indications">
        <title>Indications</title>
        <p>H2 receptor blockers, or H2 receptor antagonists (H2RAs), are gastric acid-suppressing agents frequently used in various gastric conditions. The FDA approves these drugs to treat uncomplicated gastroesophageal reflux disease (GERD), gastric or duodenal ulcers, gastric hypersecretion, and mild to infrequent heartburn or indigestion. H2 receptor antagonists may also be used off-label for stress ulcer prophylaxis, esophagitis, gastritis, gastrointestinal bleeding, or urticaria. These drugs are also sometimes included in a multidrug regimen for&#x000a0;<italic toggle="yes">Helicobacter pylori</italic>&#x000a0;eradication.<xref ref-type="bibr" rid="article-22473.r1">[1]</xref>&#x000a0;Currently,&#x000a0;3 FDA-approved H2RAs are available in the United States, either over-the-counter (OTC) or by prescription.&#x000a0;Famotidine and cimetidine are available OTC or by prescription, depending on the dose. Low-dose nizatidine is also available in OTC, but higher doses&#x000a0;require a prescription. Ranitidine was previously available but has been withdrawn in the United States&#x000a0;and suspended in&#x000a0;Europe and Australia for carcinogen contamination&#x000a0;during manufacturing.<xref ref-type="bibr" rid="article-22473.r2">[2]</xref><xref ref-type="bibr" rid="article-22473.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>H2 receptor antagonists are approved for short-term use in treating uncomplicated gastroesophageal reflux disease (GERD), gastric or duodenal ulcers, gastric hypersecretion, and mild to infrequent heartburn or indigestion.&#x000a0;IV famotidine is approved for the short-term treatment of active duodenal and gastric ulcers, maintenance therapy for patients with duodenal ulcers, short-term treatment of gastroesophageal reflux disease, erosive or ulcerative esophagitis due to GERD, and hypersecretory conditions such as Zollinger-Ellison syndrome (ZES).</p>
        <p>The American College of Gastroenterology (ACG) guidelines recommend adding bedtime H2RA for patients with persistent nocturnal symptoms while on proton pump inhibitors. In contrast, the ACG recommends proton pump inhibitors (PPIs) over H2 receptor antagonists (H2RAs) for the treatment of erosive esophagitis (EE).<xref ref-type="bibr" rid="article-22473.r4">[4]</xref>&#x000a0;ACG also advises the use of high-dose proton pump inhibitor (PPI) therapy, either continuously or intermittently, for&#x000a0;3 days following successful endoscopic hemostatic treatment of a bleeding ulcer.<xref ref-type="bibr" rid="article-22473.r5">[5]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>H2 receptor antagonists can be used off-label for esophagitis, gastritis, gastrointestinal bleeding, urticaria, and stress ulcer prophylaxis.<xref ref-type="bibr" rid="article-22473.r6">[6]</xref> These drugs are also sometimes included in a multidrug regimen for&#x000a0;<italic toggle="yes">Helicobacter pylori</italic>&#x000a0;eradication.<xref ref-type="bibr" rid="article-22473.r1">[1]</xref>&#x000a0;Although antacids are generally considered first-line agents for heartburn during pregnancy, H2 receptor antagonists may be used if needed.<xref ref-type="bibr" rid="article-22473.r7">[7]</xref>&#x000a0;H2RAs have been determined safe for use in children or adolescents with mild or infrequent heartburn symptoms that do not respond to lifestyle changes.<xref ref-type="bibr" rid="article-22473.r8">[8]</xref>&#x000a0;The overall therapeutic effectiveness of H2RAs significantly depends on the severity of the gastric disease, dosage regimen, and duration of therapy.</p>
      </sec>
      <sec id="article-22473.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells, inhibiting the binding and activity of the endogenous ligand histamine. H2 blockers thus function as competitive antagonists. Normally, gastrin stimulates histamine release from enterochromaffin-like cells after a meal, which then binds to histamine H2 receptors on gastric parietal cells,&#x000a0;causing gastric acid release. This increase in gastric acid release occurs through the activation of adenylate cyclase, which raises intracellular cyclic adenosine monophosphate (cAMP) levels. Cyclic AMP then activates protein kinase A (PKA), which phosphorylates proteins involved in moving H<sup>+</sup>/K<sup>+</sup> ATPase transporters to the plasma membrane. Increasing H<sup>+</sup>/K<sup>+</sup> ATPase transporters at the plasma membrane allows more acid secretion from parietal cells.</p>
        <p>By blocking the histamine receptor and thus&#x000a0;histamine's stimulation of parietal cell acid secretion, H2RAs suppress stimulated and basal gastric acid secretion induced by histamine.<xref ref-type="bibr" rid="article-22473.r9">[9]</xref>&#x000a0;Studies have suggested that adding an H2RA improves nocturnal intragastric pH control.<xref ref-type="bibr" rid="article-22473.r10">[10]</xref>&#x000a0;The study indicates that H2RAs have a comparatively less pronounced impact on gut microbiota than PPIs, with minimal changes in oral-to-gut transmission and microbial composition. This suggests that H2RAs may have less effect on gut microbiome alteration than PPIs.<xref ref-type="bibr" rid="article-22473.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The onset of gastric relief provided by H2RAs is approximately 60 minutes with a duration of action that ranges from 4 to 10 hours, making them useful for the on-demand treatment of occasional symptoms. All H2RAs have similar efficacy in decreasing gastric acid secretion.<xref ref-type="bibr" rid="article-22473.r12">[12]</xref><bold>&#x000a0;</bold>Famotidine is absorbed with an oral bioavailability of 40% to 45%. The presence of food may slightly increase its absorption, while antacids may slightly decrease it; these effects are not clinically significant. Peak plasma levels of famotidine are typically attained within 1 to 3 hours, and plasma levels after multiple doses are similar to those after single doses. Nizatidine has a higher oral bioavailability, often exceeding 70%. Antacids containing aluminum and magnesium hydroxides can reduce their absorption by about 10%, whereas food can increase AUC and Cmax by approximately 10%. Peak plasma concentrations of nizatidine occur within 0.5 to 3 hours after dosing. Cimetidine is rapidly absorbed, with peak plasma levels occurring within 45 to 90 minutes following oral administration. Blood concentrations of cimetidine remain high enough to inhibit 80% of basal gastric acid secretion for 4 to 5 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;Approximately 15% to 20% of famotidine in the plasma is bound to proteins. Nizatidine has a volume of distribution ranging from 0.8 to 1.5 L/kg, with about 35% bound to plasma proteins, primarily &#x003b1;1-acid glycoprotein. Although specific distribution details for cimetidine are not well-documented,&#x000a0;the drug is known to distribute widely throughout the body, including significant accumulation in the liver and kidneys.</p>
        <p><bold>Metabolism:</bold> The H2 receptor blockers are metabolized in the liver by the cytochrome P450 system. Among the H2RAs, cimetidine is&#x000a0;unique because it inhibits the CYP1A2, CYP2C9, and CYP2D6, which can lead to significant drug interactions.<xref ref-type="bibr" rid="article-22473.r13">[13]</xref></p>
        <p><bold>Elimination:</bold> Famotidine has an elimination half-life of 2.5 to 3.5 hours.&#x000a0;The drug is primarily excreted via the renal route (65% to 70%), with renal clearance ranging from 250 to 450 mL/min, indicating some tubular secretion. Nizatidine has a shorter elimination half-life of 1 to 2 hours, with plasma clearance between 40 and 60 L/h. Over 90% of the oral dose is excreted in the urine within 12 hours; about 60%&#x000a0;of the drug is&#x000a0;unchanged. Renal clearance is approximately 500 mL/min, reflecting active tubular secretion. Less than 6% of the dose is eliminated in the feces. In&#x000a0;patients with renal impairment, the half-life of nizatidine is prolonged significantly, and its clearance is decreased, necessitating dose adjustments.&#x000a0;Cimetidine has an elimination half-life of about 2 hours and&#x000a0;is primarily excreted renally.</p>
      </sec>
      <sec id="article-22473.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>H2 receptor antagonists are well-absorbed after oral administration, and all H2RAs are available as oral tablets. Nizatidine is also available as a capsule or an oral solution. Famotidine, one of the most commonly used agents, is available as a chewable tablet, oral powder for suspension, or&#x000a0;in combination formulations containing calcium carbonate and magnesium hydroxide or ibuprofen.</p>
        <p>Nizatidine is available in several formulations, including oral tablets in strengths of 150 mg and 300 mg and an over-the-counter (OTC) option of 75 mg. Cimetidine&#x000a0;is available as an injectable solution (150 mg/mL), an oral solution (150 mg/5 mL), and oral tablets in multiple strengths: 200 mg, 300 mg, 400 mg, 600 mg, and 800 mg, with higher doses available only by prescription. Famotidine is available as an injectable solution in concentrations of&#x000a0;0.4 mg/mL and 10 mg/mL, an oral suspension (40 mg/5 mL), and various oral tablets and chewable tablets available via prescription or OTC in strengths of 10 mg, 20 mg, and 40 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>H2 receptor antagonists may relieve current gastric symptoms or be taken prophylactically 30 to 60 minutes before known food or beverage triggers. H2RAs may also be taken concomitantly with antacids if both quick relief of symptoms and a longer duration of action are desired. For best results, patients should take once-daily doses of H2RAs at bedtime. More common regimens involve twice-daily dosing: once in the morning and once in the evening.<xref ref-type="bibr" rid="article-22473.r12">[12]</xref> Patients should not initially self-treat with H2RAs for longer than&#x000a0;2 weeks without consulting their primary care physician.</p>
        <p>
<bold>Famotidine&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Active duodenal ulcer:</bold>&#x000a0;40 mg once daily or 20 mg twice daily. The recommended dosage for IV famotidine is 20 mg every 12 hours.</p>
          </list-item>
          <list-item>
            <p><bold>Active gastric ulcer:</bold>&#x000a0;40 mg once daily. Malignancy should be excluded before treatment.</p>
          </list-item>
          <list-item>
            <p><bold>GERD:</bold>&#x000a0;20 mg twice daily</p>
          </list-item>
          <list-item>
            <p><bold>Erosive esophagitis:</bold>&#x000a0;20 to 40 mg twice daily</p>
          </list-item>
          <list-item>
            <p><bold>Hypersecretion pathologies:</bold>&#x000a0;20 mg every 6 hours, with adjustments based on patient needs. The maximum dose is 160 mg every 6 hours.</p>
          </list-item>
          <list-item>
            <p><bold>Maintenance of healed duodenal ulcer:</bold>&#x000a0;20 mg once daily to reduce the risk of duodenal ulcers.</p>
          </list-item>
        </list>
        <p>
<bold>Nizatidine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Active duodenal ulcer:</bold>&#x000a0;300 mg once daily or 150 mg twice daily</p>
          </list-item>
          <list-item>
            <p><bold>Maintenance of healed duodenal ulcer:</bold>&#x000a0;150 mg once daily (oral) at bedtime</p>
          </list-item>
          <list-item>
            <p><bold>GERD:</bold>&#x000a0;150 mg twice daily (oral)</p>
          </list-item>
          <list-item>
            <p><bold>Active benign gastric ulcer:</bold>&#x000a0;300 mg once daily at bedtime or 150 mg twice daily. Malignancy should be excluded before treatment.</p>
          </list-item>
        </list>
        <p>
<bold>Cimetidine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Active duodenal ulcer:</bold>&#x000a0;800 mg at bedtime, which provides effective healing, pain relief, and convenience.</p>
          </list-item>
          <list-item>
            <p><bold>Maintenance for duodenal ulcers:</bold>&#x000a0;400 mg (oral) at bedtime</p>
          </list-item>
          <list-item>
            <p><bold>GERD:</bold>&#x000a0;1600 mg daily, divided into 800 mg twice or 400 mg&#x000a0;4 times daily, for up to 12 weeks.</p>
          </list-item>
          <list-item>
            <p><bold>Hypersecretion&#x000a0;pathologies:</bold> The initial dose is 300 mg&#x000a0;4 times daily. Dosages can be adjusted based on individual needs but should not exceed 2400 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The manufacturer's labeling for famotidine and nizatidine&#x000a0;does not provide specific dosage adjustments for hepatic impairment. However, cimetidine should be used with caution in patients with hepatic impairment due to its potential for interactions.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>According to product labeling, famotidine doses should be reduced by 50%&#x000a0;for patients with a&#x000a0;creatinine clearance (CrCl) of less than 30 mL/min. For patients with similar creatinine clearances receiving cimetidine,&#x000a0;dosing should not exceed&#x000a0;300 mg every 12 hours. No adjustment is necessary for nizatidine doses for patients with&#x000a0;CrCl &#x0003e;50 mL/min. For patients with CrCl 20-50 mL/min, the recommended dose is 150 mg once daily.&#x000a0;For patients with a&#x000a0;CrCl &#x0003c;20 mL/min, the dose should be adjusted to 150 mg every other day.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Although antacids are generally considered first-line agents for heartburn during pregnancy, H2 receptor antagonists are pregnancy category B drugs. This means they are not well-studied in pregnant women but have no known teratogenic effects and may be&#x000a0;administered if needed. The minimum effective dose should be used.<xref ref-type="bibr" rid="article-22473.r7">[7]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Maternal doses of cimetidine ranging from 1000 to 1200 mg daily result in infant exposure levels considerably lower than the neonatal dosage of 5 to 10 mg/kg daily. Consequently, cimetidine is not expected to adversely affect breastfed infants, especially those&#x000a0;older than&#x000a0;2 months old. However, other medications may be preferable due to their potential to inhibit hepatic enzymes. Cimetidine can increase serum prolactin levels and has been used, though not validated, as a galactagogue.&#x000a0;With famotidine, the concentration in breast milk results in infant doses that are lower than those typically administered to newborns, suggesting that adverse effects in breastfed infants are unlikely. No special precautions are needed. Nizatidine is also minimally present in breast milk, resulting in small amounts ingested by the infant, and is not expected to cause adverse effects. No specific precautions are required for nizatidine. H2 receptor antagonists with more extensive clinical use might be preferable in newborns.<xref ref-type="bibr" rid="article-22473.r14">[14]</xref><xref ref-type="bibr" rid="article-22473.r15">[15]</xref><xref ref-type="bibr" rid="article-22473.r16">[16]</xref></p>
        <p><bold>Pediatric patients:</bold> H2RAs have also been&#x000a0;determined safe for children or adolescents with mild or infrequent heartburn symptoms that do not respond to lifestyle changes.<xref ref-type="bibr" rid="article-22473.r8">[8]</xref> According to the American Academy of Pediatrics (AAP), GERD syrup/suspension formulations are preferred.&#x000a0;Cimetidine is dosed at 30 to 40 mg/kg per day, divided into&#x000a0;4 doses, for patients aged 16 years and older. Famotidine is administered at 1 mg/kg daily, divided into&#x000a0;2 doses, for children aged 12 months to 16 years. The maximum dose of famotidine is 40 mg per day. Nizatidine is dosed at 10 mg/kg per day, divided into&#x000a0;2 doses, for individuals aged 12 years and older.<xref ref-type="bibr" rid="article-22473.r17">[17]</xref></p>
        <p><bold>Older patients:</bold> H2RA dosing is similar to adult dosing. As explained above, adjustment for renal function is necessary. Previous studies have investigated the potential link between dementia and long-term use of H2RAs. A recent study, however, found no significant association between H2RA use and cognitive impairment or dementia. Further research is required to understand this relationship better.<xref ref-type="bibr" rid="article-22473.r18">[18]</xref></p>
      </sec>
      <sec id="article-22473.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>H2 receptor antagonists are generally well-tolerated. Mild side effects may include headache, drowsiness, fatigue, abdominal pain, constipation, or diarrhea.<xref ref-type="bibr" rid="article-22473.r19">[19]</xref>&#x000a0;The&#x000a0;administration of H2RAs&#x000a0;to patients with renal impairment, hepatic impairment, or who are older than 50&#x000a0;is associated with central nervous system side effects such as delirium, confusion, hallucinations,&#x000a0;and slurred speech. Cimetidine&#x000a0;is generally considered the most&#x000a0;likely H2 blocker to cause these symptoms, although similar effects have also occurred with famotidine administration.<xref ref-type="bibr" rid="article-22473.r20">[20]</xref><xref ref-type="bibr" rid="article-22473.r21">[21]</xref><xref ref-type="bibr" rid="article-22473.r22">[22]</xref></p>
        <p>Using&#x000a0;H2 receptor antagonists&#x000a0;regularly&#x000a0;may result in tachyphylaxis or tolerance, limiting their use as maintenance&#x000a0;therapy for GERD symptoms. Tolerance to these effects can occur&#x000a0;after 7 to 14 days of continued treatment. Intermittent or as-needed administration may help prevent the development of tachyphylaxis.<xref ref-type="bibr" rid="article-22473.r23">[23]</xref></p>
        <p>H2RAs&#x000a0;have&#x000a0;a relatively minor risk of developing bacterial overgrowth and infections compared to PPIs.<xref ref-type="bibr" rid="article-22473.r24">[24]</xref>&#x000a0;Recent studies indicate an association between rosacea and H2RAs; further research is required.<xref ref-type="bibr" rid="article-22473.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>As a result of the intended elevation in gastric pH, drugs requiring an acidic environment for dissolution and absorption&#x000a0;may become less effective. Cimetidine is a potent cytochrome P450 (CYP450) enzyme inhibitor and should be avoided with other medications metabolized by CYP450 enzymes, such as theophylline, selective serotonin reuptake inhibitors, or warfarin. Prolonged, high doses of cimetidine have also been linked to gynecomastia, reduced sperm count, and impotence in men,&#x000a0;as well as galactorrhea in women. These conditions typically resolve with drug discontinuation. Clinicians generally avoid cimetidine as a treatment&#x000a0;for gastric symptoms.<xref ref-type="bibr" rid="article-22473.r26">[26]</xref>&#x000a0;Excessive use of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) may predispose individuals to iron deficiency anemia, although direct clinical evidence is limited.<xref ref-type="bibr" rid="article-22473.r27">[27]</xref>&#x000a0;A case-control study using Korean National Health Insurance data from 2014 to 2020 found that the combined use of PPIs and H2RAs was associated with an increased risk of osteoporotic fractures; further research is required. However, this combination should be used cautiously.<xref ref-type="bibr" rid="article-22473.r28">[28]</xref></p>
      </sec>
      <sec id="article-22473.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are currently no absolute contraindications to H2RA therapy. However,&#x000a0;these drugs should not be used in patients with known hypersensitivity to any H2RA or formulation components.<xref ref-type="bibr" rid="article-22473.r29">[29]</xref>&#x000a0;Cross-sensitivity has been reported. Patients should stop using OTC H2RAs if they experience difficulty or pain when swallowing, vomiting with blood, or bloody or black stools.&#x000a0;These patients should seek&#x000a0;immediate medical attention.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Prior recalls of ranitidine: The FDA recalled ranitidine tablets due to unacceptable levels of N-nitrosodimethylamine (NDMA), a potential carcinogen.<xref ref-type="bibr" rid="article-22473.r30">[30]</xref></p>
      </sec>
      <sec id="article-22473.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients using H2RAs should be monitored for endoscopic improvement and decreased gastric symptoms to assess the&#x000a0;clinical effectiveness and need for therapy adjustments. Patients should also be monitored for adverse effects and possible drug interactions, especially when taking cimetidine.</p>
        <p>Famotidine and nizatidine require dose adjustment for patients with a creatine clearance of less than 50 mL/min. Cimetidine doses should be reduced for patients with a creatine clearance of less than 30 mL/min. The half-life of cimetidine may become prolonged in patients with hepatic impairment, but for all&#x000a0;H2RAs, no dose adjustments are required for hepatic impairment unless also accompanied by renal impairment.</p>
        <p>Rarely, QT-prolongation or central nervous system effects have been observed in patients&#x000a0;with impaired renal function&#x000a0;receiving standard doses. Famotidine use requires caution during renal impairment and in combination with other QT-prolonging medications or conditions. Older patients should also be monitored for adverse central nervous system effects such as dizziness or confusion resulting&#x000a0;from decreased drug clearance.<xref ref-type="bibr" rid="article-22473.r31">[31]</xref></p>
      </sec>
      <sec id="article-22473.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>H2 receptor antagonists have a broad therapeutic index; severe toxicity is rare. Toxic H2RA levels may&#x000a0;cause inhibition of H2 receptors in the myocardium and central nervous system. Central nervous system depression, hypotension, and bradycardia&#x000a0;are rare but have been&#x000a0;observed after rapid intravenous H2RA infusion.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment for H2RA overdose typically involves discontinuation of the drug and supportive care measures and may include decontamination with gastric lavage or activated charcoal.</p>
      </sec>
      <sec id="article-22473.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Many H2 blockers are available over the counter. While these drugs are relatively safe, they may produce severe adverse effects when combined with other CNS drugs. Patient education by the interprofessional healthcare team is critical to preventing toxicity and improving outcomes for patients receiving H2 receptor-blocking therapy. Pharmacists&#x000a0;should check for drug interactions and inquire of patients in the retail setting if they encounter a patient purchasing H2 receptor antagonists as an over-the-counter option. Patients should be advised not to combine these agents with other CNS drugs or alcohol and refrain from taking them for prolonged periods.<xref ref-type="bibr" rid="article-22473.r32">[32]</xref>&#x000a0;An interprofessional team approach and communication among clinicians (MD, DO, NP, PA), pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes&#x000a0;related&#x000a0;to H2 blockers.</p>
      </sec>
      <sec id="article-22473.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22473">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22473/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22473">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22473.s11">
        <title>References</title>
        <ref id="article-22473.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappa</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Buaron</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Mussari</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ciociola</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-73</page-range>
            <pub-id pub-id-type="pmid">10215730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruepp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;tschl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bream</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Filancia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spinei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whomsley</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The EU Response to the Presence of Nitrosamine Impurities in Medicines.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>782536</fpage>
            <pub-id pub-id-type="pmid">34869504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Florian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keire</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk of N-Nitrosodimethylamine (NMDA) Formation With Ranitidine.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Nov</month>
            <day>23</day>
            <volume>326</volume>
            <issue>20</issue>
            <fpage>2077</fpage>
            <pub-id pub-id-type="pmid">34812875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Schnoll-Sussman</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Yadlapati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spechler</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-56</page-range>
            <pub-id pub-id-type="pmid">34807007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barkun</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Martel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leontiadis</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>899</fpage>
            <page-range>899-917</page-range>
            <pub-id pub-id-type="pmid">33929377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>16</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>18467</fpage>
            <pub-id pub-id-type="pmid">34531488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Servey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Over-the-Counter Medications in Pregnancy.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Oct</month>
            <day>15</day>
            <volume>90</volume>
            <issue>8</issue>
            <fpage>548</fpage>
            <page-range>548-55</page-range>
            <pub-id pub-id-type="pmid">25369643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattos</surname>
                <given-names>&#x000c2;Z</given-names>
              </name>
              <name>
                <surname>Marchese</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Kupski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.</article-title>
            <source>Arq Gastroenterol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-280</page-range>
            <pub-id pub-id-type="pmid">28954042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacFarlane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Management of gastroesophageal reflux disease in adults: a pharmacist's perspective.</article-title>
            <source>Integr Pharm Res Pract</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>41</fpage>
            <page-range>41-52</page-range>
            <pub-id pub-id-type="pmid">29892570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mainie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tutuian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castell</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>676</fpage>
            <page-range>676-9</page-range>
            <pub-id pub-id-type="pmid">18496394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.</article-title>
            <source>Gut</source>
            <year>2024</year>
            <month>Jun</month>
            <day>06</day>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>1087</fpage>
            <page-range>1087-1097</page-range>
            <pub-id pub-id-type="pmid">38050061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pettit</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of gastroesophageal reflux disease.</article-title>
            <source>Pharm World Sci</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>432</fpage>
            <page-range>432-5</page-range>
            <pub-id pub-id-type="pmid">16341949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Histamine Type-2 Receptor Antagonists (H2 Blockers)</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31643264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Nizatidine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Famotidine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>9</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Cimetidine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lightdale</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gremse</surname>
                <given-names>DA</given-names>
              </name>
              <collab>Section on Gastroenterology, Hepatology, and Nutrition</collab>
            </person-group>
            <article-title>Gastroesophageal reflux: management guidance for the pediatrician.</article-title>
            <source>Pediatrics</source>
            <year>2013</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>e1684</fpage>
            <page-range>e1684-95</page-range>
            <pub-id pub-id-type="pmid">23629618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kochar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lockery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fravel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahady</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>McNeil</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study.</article-title>
            <source>Gastroenterology</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>564</fpage>
            <page-range>564-572.e1</page-range>
            <pub-id pub-id-type="pmid">37315867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto-Sanchez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bercik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moayyedi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Proton pump inhibitors for functional dyspepsia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Mar</month>
            <day>08</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD011194</fpage>
            <pub-id pub-id-type="pmid">28271513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Einsiedel</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Roesch-Ely</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diebold</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sartor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mundt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergemann</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>152</fpage>
            <page-range>152-4</page-range>
            <pub-id pub-id-type="pmid">12163986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teramoto</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reversible adverse effects on the CNS induced by histamine H2 receptor antagonists.</article-title>
            <source>Eur Neurol</source>
            <year>1998</year>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <pub-id pub-id-type="pmid">9635477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werbel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Ranitidine-Associated Sleep Disturbance: Case Report and Review of H2 Antihistamine-Related Central Nervous System Adverse Effects.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e2414</fpage>
            <pub-id pub-id-type="pmid">29872595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Muniraj</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Therapies in Gastrointestinal Diseases.</article-title>
            <source>Med Clin North Am</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>827</fpage>
            <page-range>827-50</page-range>
            <pub-id pub-id-type="pmid">27235617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Untersmayr</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Acid suppression therapy and allergic reactions.</article-title>
            <source>Allergo J Int</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>303</fpage>
            <page-range>303-311</page-range>
            <pub-id pub-id-type="pmid">28603686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Her</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Association Between Acid-Suppressive Drugs and Risk of Rosacea: Retrospective Study Using the Korean National Health Insurance Service-National Sample Cohort.</article-title>
            <source>J Korean Med Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>04</day>
            <volume>38</volume>
            <issue>47</issue>
            <fpage>e402</fpage>
            <pub-id pub-id-type="pmid">38050914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humphries</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Merritt</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Review article: drug interactions with agents used to treat acid-related diseases.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>13 Suppl 3</volume>
            <fpage>18</fpage>
            <page-range>18-26</page-range>
            <pub-id pub-id-type="pmid">10491725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinnakota</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Brett</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Iron Deficiency Anemia Associated With Acid-Modifying Medications: Two Cases and Literature Review.</article-title>
            <source>Am J Med Sci</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>357</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-163</page-range>
            <pub-id pub-id-type="pmid">30528320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.</article-title>
            <source>Korean J Intern Med</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-237</page-range>
            <pub-id pub-id-type="pmid">38321358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-31</page-range>
            <pub-id pub-id-type="pmid">21461253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Ranitidine's N-nitrosodimethylamine Problem May be Tip of the Iceberg.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Jan</month>
            <day>04</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>e2035158</fpage>
            <pub-id pub-id-type="pmid">33512513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Joseph</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.</article-title>
            <source>Ann Pharmacother</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>1532</fpage>
            <page-range>1532-7</page-range>
            <pub-id pub-id-type="pmid">8305790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22473.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hassanin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>177</volume>
            <issue>6</issue>
            <fpage>871</fpage>
            <pub-id pub-id-type="pmid">28437544</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
